Neumora Therapeutics, Inc.
NMRA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001885522
In the last 90 days, Neumora Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 113 institutions reported holding it in 13F filings for Q2 2026, worth $129.2M in total; no superinvestor holds it.
Superinvestors holding NMRA, Q2 2026
No superinvestor reported holding NMRA in Q2 2026.
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of NMRA each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q1 2024
0 superinvestors holding at quarter end
- Sold out
- HHLR Advisors (Hillhouse)
Q4 2023
1 superinvestor holding at quarter end
- Sold out
- Soros Fund Management
Q3 2023
2 superinvestors holding at quarter end